The simultaneous implementation of anti-TIGIT and anti-PD-1 agents was beneficial in head and neck squamous cell carcinoma [135], glioblastoma [85], colorectal cancer [136], and renal cancer [137]. The gene discussed is PDCD1; the disease is renal carcinoma.